- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03373097
Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors
Phase I/II Study of Anti-GD2 Chimeric Antigen Receptor-Expressing T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors
The purpose of this study is to test the safety and efficacy of GD2-CART01, a CAR T cell treatment targeting GD2 in paediatric or young adult patients with High Risk and/or relapsed/refractory Neuroblastoma.
A small exploratory cohort of patients with GD2-positive tumors other than Neuroblastoma has also been included.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study will consist of 2 phases, a Phase I or dose escalation phase and a Phase II or expansion phase. Paediatric or young adult patients with relapsed High Risk and/or relapsed/refractory Neuroblastoma will be enrolled in the study.
After completion of the phase I portion of the study, a small cohort of patients with GD2-positive tumors other than Neuroblastoma has also been included.
Eligible patients will undergo leukapheresis in order to harvest T cells, which will be manufactured to obtain the autologous CAR T product GD2-CART01, a GD2-targeting CAR T product. Briefly, the patients will be treated with a lymphodepleting regimen containing conventional chemotherapic agents and subsequently will receive a single infusion of GD2-CART01. Moreover, the product contains a suicide gene safety switch (namely inducible Caspase 9): in case of relevant toxicities, the patient will receive the dimerizing agent in order to activate the apoptotic pathway in the infused T cells.
After infusion of CAR T cells, the patients will enter a 5-year active follow-up period.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Franco Locatelli, MD, PhD
- Phone Number: 2678 066859
- Email: franco.locatelli@opbg.net
Study Locations
-
-
-
Roma, Italy
- Recruiting
- Ospedale Pediatrico Bambino Gesù
-
Principal Investigator:
- Franco Locatelli, MD, PhD
-
Contact:
- Franco Locatelli, MD, PhD
- Phone Number: 2678 066859
- Email: franco.locatelly@opbg.net
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Phase I The patient must meet the following eligibility inclusion criteria to be enrolled to receive treatment in the Phase I study.
Diagnosis of NBL that have been treated with frontline therapy and is judged to be incurable, based upon the following criteria:
- Relapse after first-line treatment, proved by a positive 123-I-mMIBG-scan
- Persistence/progression of disease after the initiation of the upfront treatment
- Patients must have measurable or evaluable disease at the time of treatment enrollment, as shown by bone marrow biopsy/aspirate, US or CT/MRI scan or by 123-I-mMIBG scan.
- Recover from the toxic effect of previous chemotherapies: grade 4 and or 3 non-hematologic toxicities must have resolved to grade ≤2; if some effects of the therapies have become chronic (i.e. treatment associated thrombocytopenia), the patient must be clinically stable, according to the opinion of the treating physicians, and meet all other eligibility criteria.
- Age: 12 months -18 years.
- Voluntary informed consent is given. For subjects < 18 years old their legal guardian must give informed consent. Pediatric subjects will be included in age appropriate discussion and verbal assent will be obtained for those greater than or equal to 12 years of age, when appropriate.
- Clinical performance status: Patients > 16 years of age: Karnofsky greater than or equal to 60%; Patients less than or equal to 16 years of age: Lansky scale greater than or equal to 60%.
- Patients of child-bearing or child-fathering potential must be willing to practice birth control from the time of enrollment on this study and for four months after receiving the preparative regimen.
- Females of child-bearing potential must have a negative pregnancy test because of the potentially dangerous effects on the fetus.
Phase II
The patient must meet the following eligibility inclusion criteria to be enrolled to receive treatment in the Phase II study.
Diagnosis of NBL that have been treated with frontline therapy and is judged to be incurable, based upon the following criteria:
- Relapse after first-line treatment, proved by a positive MIBG-scan
- Persistence/progression of disease after the initiation of the upfront treatment
OR
Diagnosis of extremely High Risk NBL at high risk of relapse, defined by stage III/IV and Myc-N amplification, at the end of the first-line treatment according to the Standard of Care, even if NED.
OR
- Diagnosis of GD2+ tumors other than Neuroblastoma, considered incurable with conventional treatments by the treating physician.
- Patients with relapsed/refractory disease must have measurable or evaluable disease at the time of treatment enrollment, as shown by bone marrow biopsy/aspirate, US or CT/MRI scan or by MIBG-scan.
- Recover from the toxic effect of previous chemotherapies: grade 4 and or 3 non-hematologic toxicities must have resolved to grade ≤2; if some effects of the therapies have become chronic (i.e. treatment associated thrombocytopenia), the patient must be clinically stable, according to the opinion of the treating physicians, and meet all other eligibility criteria.
- Age: 12 months - 18 years.
- Voluntary informed consent is given. For subjects < 18 years old their legal guardian must give informed consent. Pediatric subjects will be included in age appropriate discussion and verbal assent will be obtained for those greater than or equal to 12 years of age, when appropriate.
- Clinical performance status: Patients > 16 years of age: Karnofsky greater than or equal to 60%; Patients less than or equal to 16 years of age: Lansky scale greater than or equal to 60%.
- Patients of child-bearing or child-fathering potential must be willing to practice birth control from the time of enrollment on this study and for four months after receiving the preparative regimen.
- Females of child-bearing potential must have a negative pregnancy test because of the potentially dangerous effects on the fetus
Exclusion Criteria:
- Pregnant or lactating women
- Severe, uncontrolled active intercurrent infections
- Active hepatitis B or hepatitis C infection
- HIV infection
- Rapidly progressive disease with life-expectancy < 6 weeks
- History of grade 3 or 4 hypersensitivity to murine protein-containing products
- Hepatic function: Inadequate liver function defined as total bilirubin > 4x upper limit of normal (ULN) or transaminase (ALT and AST) > 6 x ULN based on age and laboratory specific normal ranges
- Renal function: serum creatinine > 3x ULN for age.
- Blood oxygen saturation < 90%.
- Cardiac function: Left ventricular ejection fraction lower than 45% by ECHO.
- Marrow function: ANC lower than 500/mm3 and/or platelets lower than 20.000 (not reached by transfusion).
- Congestive heart failure, cardiac arrhythmia, psychiatric illness, or social situations that would limit compliance with study requirements or in the opinion of the PI would pose an unacceptable risk to the subject.
- Untreated CNS metastasis; patients with previous CNS tumor involvement that has been treated and is stable for at least 6 weeks following completion of therapy are eligible.
Concurrent or recent prior therapies, before infusion:
- Systemic steroids (at a dose equivalent to or greater 2 mg/kg prednisone) in the 2 weeks before infusion. Recent or current use of inhaled/topical/non-absorbable steroids is not exclusionary.
- Systemic chemotherapy in the 2 weeks preceding infusion.
- Immunosuppressive agents less than or equal to 30 days.
- Radiation therapy must have been completed at least 3 weeks prior to enrollment.
- I131-MIBG therapy must have been completes at least 6 weeks prior to enrollment
- Anti-GD2 murine monoclonal antibody (ch14.18 antibody) in the 2 weeks preceding infusion
- Other anti-neoplastic investigational agents currently or within 30 days prior to start of protocol therapy;
- Exceptions:
- Subjects receiving steroid therapy at physiologic replacement doses only are allowed provided there has been no increase in dose for at least 2 weeks prior to starting apheresis
- Patient-derived GD2-CART01 production failure.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: GD2-CART01
After a lymphodepleting regimen the patients will receive 1.0 to 10.0 x 10⁶/kg GD2 Chimeric Antigen Receptor (CAR) positive T cells.
|
Following a lymphodepleting treatment with conventional chemotherapy, patients will be treated with 1.0 to 10.0 x 10⁶/kg GD2 Chimeric Antigen Receptor (CAR) positive T cells as a single dose.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase I - Identification of the dose limiting toxicity (DLT)
Time Frame: 4 weeks after T cell infusion
|
Toxicity will be assessed according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) scale, version 4 and the number of patients experiencing DLT will be evaluated
|
4 weeks after T cell infusion
|
Phase II - Antitumor effect
Time Frame: Up to 6 months after T cell infusion
|
Assessment of Best Overall Response (BOR)
|
Up to 6 months after T cell infusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
In vivo persistence/expansion of infused CAR T cell
Time Frame: UP to 5 years
|
Detection of infused CAR T cell in the peripheral and bone marrow blood
|
UP to 5 years
|
Serum cytokine profiling
Time Frame: First 2 weeks after T cell infusion
|
Assessment of the seric cytokines profile
|
First 2 weeks after T cell infusion
|
Time To Progression (TTP)
Time Frame: Up 5 years after T cell infusion
|
Up 5 years after T cell infusion
|
|
Event-Free Survival (EFS)
Time Frame: Up 5 years after T cell infusion
|
Up 5 years after T cell infusion
|
|
Overall Survival (OS)
Time Frame: Up 5 years after T cell infusion
|
Up 5 years after T cell infusion
|
|
Disease outcome according to INRC vs irRC
Time Frame: Up to 5 years
|
Tumor response assessment through the two different criteria
|
Up to 5 years
|
Elimination of CAR T cell through iC9 in case of toxicity
Time Frame: Up to 15 years
|
Assessment of the kinetic of CAR T cell elimination after infusion of the dimerizer
|
Up to 15 years
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neoplasms, Bone Tissue
- Neoplasms, Connective Tissue
- Neuroectodermal Tumors, Primitive
- Neuroectodermal Tumors, Primitive, Peripheral
- Sarcoma
- Sarcoma, Ewing
- Osteosarcoma
- Neuroblastoma
Other Study ID Numbers
- GD2CAR01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sarcoma
-
Albert Einstein College of MedicineNational Cancer Institute (NCI)TerminatedUterine Corpus Leiomyosarcoma | Stage IIA Uterine Sarcoma | Stage IIB Uterine Sarcoma | Stage IIIA Uterine Sarcoma | Stage IIIB Uterine Sarcoma | Stage IIIC Uterine Sarcoma | Stage IVA Uterine Sarcoma | Stage IVB Uterine Sarcoma | Stage IA Uterine Sarcoma | Stage IB Uterine Sarcoma | Stage IC Uterine SarcomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedBone Sarcoma | Retroperitoneal Sarcoma | Adult Soft Tissue SarcomaUnited States
-
National Cancer Institute (NCI)RecruitingMetastatic Alveolar Soft Part Sarcoma | Unresectable Alveolar Soft Part Sarcoma | Advanced Soft Tissue Sarcoma | Advanced Alveolar Soft Part SarcomaUnited States
-
Mohammed M MilhemGenentech, Inc.CompletedSarcoma | Soft Tissue Sarcoma | Metastatic Sarcoma | Locally Advanced Sarcoma | Unresectable SarcomaUnited States
-
National Cancer Institute (NCI)RecruitingMetastatic Leiomyosarcoma | Unresectable Leiomyosarcoma | Metastatic Sarcoma | Unresectable Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Unresectable SarcomaUnited States
-
National Cancer Institute (NCI)CompletedRhabdomyosarcoma | Synovial Sarcoma | Ewing's Sarcoma | MPNST | High-risk SarcomaUnited States
-
Brown UniversityActuate Therapeutics Inc.WithdrawnSoft Tissue Sarcoma | Osteosarcoma | Ewing Sarcoma of Bone | Leiomyosarcoma | High Grade Sarcoma | Liposarcoma | Rhabdomyosarcoma | Angiosarcoma | Bone Sarcoma | Synovial Sarcoma | Undifferentiated Pleomorphic Sarcoma | Myxofibrosarcoma | Spindle Cell SarcomaUnited States
-
Epizyme, Inc.RecruitingAdvanced Soft-tissue Sarcoma | Advanced Epithelioid SarcomaUnited States, Taiwan, Canada, United Kingdom
-
Centre Oscar LambretFrench Sarcoma Group; Study Group of Bone TumorsCompletedSoft Tissue Sarcoma | Uterine SarcomaFrance
-
Advenchen Laboratories, LLCActive, not recruitingLeiomyosarcoma | Synovial Sarcoma | Alveolar Soft Part Sarcoma | Soft-Tissue SarcomaUnited States, United Kingdom, Spain, China, Italy
Clinical Trials on GD2-CART01
-
Bambino Gesù Hospital and Research InstituteRecruitingHigh Grade Glioma | Medulloblastoma, Childhood | Diffuse Intrinsic Pontine Glioma | Diffuse Midline Glioma | Embryonal Tumor | Brain Tumor Adult | Brain Tumor, PediatricItaly
-
Shenzhen Geno-Immune Medical InstituteUnknown
-
Bambino Gesù Hospital and Research InstituteNot yet recruitingT-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
-
University College, LondonNot yet recruiting
-
Sinobioway Cell Therapy Co., Ltd.Children's Hospital of Fudan University; Nanjing Children's HospitalUnknownRelapsed or Refractory NeuroblastomaChina
-
University College, LondonRecruiting
-
UNC Lineberger Comprehensive Cancer CenterUnited States Department of Defense; Bellicum PharmaceuticalsRecruitingSmall Cell Lung Carcinoma | Lung Cancer | Non Small Cell Lung CancerUnited States
-
Shenzhen Geno-Immune Medical InstituteRecruiting
-
Shenzhen Geno-Immune Medical InstituteShenzhen Children's HospitalRecruiting
-
Shenzhen Geno-Immune Medical InstituteRecruiting